We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

DiaMedica Therapeutics Inc (DMAC) NPV

Sell:$5.20 Buy:$5.30 Change: $0.12 (2.14%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$5.20
Buy:$5.30
Change: $0.12 (2.14%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$5.20
Buy:$5.30
Change: $0.12 (2.14%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Contact details

Address:
301 CARLSON PARKWAY, SUITE 210
MINNEAPOLIS
55305
United States
Telephone:
+1 (763) 4965454
Website:
https://www.diamedica.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DMAC
ISIN:
CA25253X2077
Market cap:
$224.92 million
Shares in issue:
42.76 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Canada
Currency:
US dollar
Indices:
n/a

Key personnel

  • Rick Pauls
    President, Chief Executive Officer, Director
  • Scott Kellen
    Chief Financial Officer, Company Secretary
  • Ambarish Shah
    Chief Technology Officer
  • Dominic Cundari
    Chief Commercial Officer
  • Lorianne Masuoka
    Chief Medical Officer
  • David Wambeke
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.